PARAMOUNT, the First Randomized Trial of AI-Enabled Plaque-Based Care, Meets Primary Endpoint in Late-Breaking Results at AHA 2026
DENVER–(BUSINESS WIRE)– #AI–Cleerly, a leader in advanced cardiovascular imaging analysis, today presented primary results from PARAMOUNT, the first randomized trial of AI-QCT-guided care against usual care, as Late-Breaking Science at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. Compared with usual care based on stress testing, care guided by AI-based quantitative coronary CT analysis (AI-QCT) improved diagnostic certainty and led to more patients receiving lipid-lowe